Prior clinical trials have studied the use of thrombopoietin receptor agonists among such patients with prolonged thrombocytopenia after HSCT and have demonstrated exceedingly poor survival despite numerical improvements in platelet counts [12, 18]. The gene discussed is MPL; the disease is Thrombocytopenia.